MX2021001084A - Terapia de combinacion para el tratamiento del cancer. - Google Patents

Terapia de combinacion para el tratamiento del cancer.

Info

Publication number
MX2021001084A
MX2021001084A MX2021001084A MX2021001084A MX2021001084A MX 2021001084 A MX2021001084 A MX 2021001084A MX 2021001084 A MX2021001084 A MX 2021001084A MX 2021001084 A MX2021001084 A MX 2021001084A MX 2021001084 A MX2021001084 A MX 2021001084A
Authority
MX
Mexico
Prior art keywords
treating cancer
combination therapy
administering
subject
effective amount
Prior art date
Application number
MX2021001084A
Other languages
English (en)
Inventor
Wolfram Brugger
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021001084A publication Critical patent/MX2021001084A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)

Abstract

Se divulgan métodos para tratar el cáncer, que comprenden, administrar a un sujeto que lo necesite y que comprenden administrar al sujeto, una cantidad eficaz de una composición farmacéutica que comprende una pluralidad de nanopartículas AZD2811 y una cantidad eficaz de 5-azacitidina.
MX2021001084A 2018-07-30 2019-07-26 Terapia de combinacion para el tratamiento del cancer. MX2021001084A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711753P 2018-07-30 2018-07-30
US201862727152P 2018-09-05 2018-09-05
PCT/IB2019/056403 WO2020026102A1 (en) 2018-07-30 2019-07-26 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
MX2021001084A true MX2021001084A (es) 2021-05-12

Family

ID=68069817

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001084A MX2021001084A (es) 2018-07-30 2019-07-26 Terapia de combinacion para el tratamiento del cancer.

Country Status (11)

Country Link
US (1) US20210315898A1 (es)
EP (1) EP3829586A1 (es)
JP (1) JP2021533112A (es)
KR (1) KR20210039414A (es)
CN (1) CN112533605A (es)
AU (1) AU2019312904A1 (es)
CA (1) CA3106783A1 (es)
MA (1) MA53341A (es)
MX (1) MX2021001084A (es)
TW (1) TW202019440A (es)
WO (1) WO2020026102A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021037933A1 (en) * 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
RU2682332C2 (ru) 2013-09-16 2019-03-19 Астразенека Аб Терапевтические полимерные наночастицы и способы их получения и применения

Also Published As

Publication number Publication date
JP2021533112A (ja) 2021-12-02
MA53341A (fr) 2021-11-03
AU2019312904A1 (en) 2021-03-11
WO2020026102A1 (en) 2020-02-06
CA3106783A1 (en) 2020-02-06
EP3829586A1 (en) 2021-06-09
KR20210039414A (ko) 2021-04-09
CN112533605A (zh) 2021-03-19
US20210315898A1 (en) 2021-10-14
TW202019440A (zh) 2020-06-01

Similar Documents

Publication Publication Date Title
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2017007321A (es) Terapias de combinacion.
WO2016025635A3 (en) Combination therapy for treating cancer
WO2017079746A3 (en) Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
MX2018008514A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX2020003719A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
NZ700759A (en) Combination therapy for treating cancer
SG10201902664RA (en) Combination therapy for treating cancer
MY166014A (en) Combination therapy methods for treating proliferative diseases
WO2016043874A3 (en) Combination therapy for treating cancer
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2020001727A (es) Terapia de combinacion.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2018007823A (es) Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal.
MX2019013862A (es) Terapia de combinacion.
MX2018016332A (es) Quimioterapias de combinacion.
MX2020007130A (es) Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl.
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
MX2020011817A (es) Metodos para tratar el linfoma.